Effects of TZD use and discontinuation on fracture rates in ACCORD bone study

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 11, 2015, Pages 4059-4066

  Schwartz, Ann V ^a   Chen, Haiying ^b   Ambrosius, Walter T ^b   Sood, Ajay ^c   Josse, Robert G ^d   Bonds, Denise E ^e   Schnall, Adrian M ^c   Vittinghoff, Eric ^a   Bauer, Douglas C ^a   Banerji, Mary Ann ^f   Cohen, Robert M ^g   Hamilton, Bruce P ^h   Isakova, Tamara ⁱ   Sellmeyer, Deborah E ^j   Simmons, Debra L ^k   Shibli Rahhal, Amal ^l   Williamson, Jeff D ^b   Margolis, Karen L ^m  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MIAMI   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF UTAH   (United States)

^l UNIVERSITY OF IOWA   (United States)

^m Health Partners Institute for Education and Research   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE;

AGED; COHORT ANALYSIS; COMPLICATION; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW UP; FRACTURES, BONE; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 84958640485     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-1215     Document Type: Article

References (27)

1. Cauley JA. Public health impact of osteoporosis. J Gerontol A Biol Sci Med Sci. 2013;68(10):1243-1251.
2. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int. 2007;18(4):427-444.
3. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009; 180(1):32-39.
4. Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone. 2014; 68:115-123.
5. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008; 168(8):820-825.
6. Douglas IJ, Evans SJ, Pocock S, Smeeth L. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med. 2009;6(9):e1000154.
7. Kumar S, Hoffman SJ, Samadfam R, et al. The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate. J Bone Miner Res. 2013;28(7):1653-1665.
8. Bilezikian JP, Josse RG, Eastell R, et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98(4):1519-1528.
9. Schwartz AV, Margolis KL, Sellmeyer DE, et al. Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial. Diabetes Care. 2012;35(7):1525-1531.
10. Buse JB, Bigger JT, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99(12A):21i-33i.
11. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24): 2545-2559.
12. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31:845-851.
13. Hamann C, Kirschner S, Günther KP, Hofbauer LC. Bone, sweet bone-osteoporotic fractures in diabetes mellitus. Nat Rev Endocrinol. 2012;8(5):297-305.
14. Vittinghoff E, Glidden DV, Shiboski SC, McCulloch CE. Regression methods in biostatistics: linear, logistic, survival, and repeated measures models. 2nd ed. San Francisco, CA: Springer; 2012.
15. HomePD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-2135.
16. Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome proliferator-activated receptor α ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res. 2000;60(6):1604-1608.
17. Seto-Young D, Avtanski D, Parikh G, et al. Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase. Horm Metab Res. 2011;43(4):250-256.
18. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15(6):993-1000.
19. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferatoractivated receptor-α agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007;92(4): 1305-1310.
20. Berberoglu Z, Yazici AC, Demirag NG. Effects of rosiglitazone on bone mineral density and remodelling parameters in postmenopausal diabetic women: a 2-year follow-up study. Clin Endocrinol (Oxf). 2010;73(3):305-312.
21. Borges JL, Bilezikian JP, Jones-Leone AR, et al. A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-na?ve type 2 diabetes mellitus patients. Diabetes Obes Metab. 2011;13(11):1036-1046.
22. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2008;93(5):1696-1701.
23. Bone HG, Lindsay R, McClung MR, Perez AT, Raanan MG, Spanheimer RG. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2013;98(12):4691-4701.
24. Grey A, Bolland M, Fenwick S, et al. The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. Eur J Endocrinol. 2014;170(2):255-262.
25. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009; 32(3):187-202.
26. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561-1573.
27. White E. The effect of misclassification of disease status in follow-up studies: implications for selecting disease classification criteria.AmJ Epidemiol. 1986;124(5):816-825.